

## Title (en)

PERFLUOROCARBON AND HYDROFLUOROCARBON FORMULATIONS AND METHODS OF MAKING AND USING SAME

## Title (de)

FORMULIERUNGEN AUS VOLLHALOGENIERTEM FLUORKOHLLENWASSERSTOFF UND HYDROFLUORKOHLLENWASSERSTOFF SOWIE VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG

## Title (fr)

PREPARATIONS DE PERFLUOROCARBURE ET D'HYDROFLUOROCARBURE ET PROCEDES DE FABRICATION ET D'UTILISATION DE CELLES-CI

## Publication

**EP 1599184 A4 20090624 (EN)**

## Application

**EP 03790479 A 20031215**

## Priority

- US 0339561 W 20031215
- US 44462103 P 20030204

## Abstract (en)

[origin: WO2004071488A1] A liquid aerosol generating formulation comprising medicament and at least one liquid perfluorocarbon and/or hydrofluorocarbon. The formulation can include at least one surfactant which stabilizes the medicament. An aerosol of medicament particles can be formed by heating the formulation in a flow passage such that the liquid perfluorocarbon and/or hydrofluorocarbon is vaporized and expands out of an outlet of the flow passage. The flow passage can be a heated capillary sized flow passage in a hand held inhaler. The liquid perfluorocarbon and/or hydrofluorocarbon can deliver drugs having low solubility and/or low potency to a patient as a soft mist aerosol requiring minimal patient coordination.

## IPC 1-7

**A61K 9/00**; **A61K 9/72**; **A61K 9/14**; **A61K 9/16**; **A61K 39/00**

## IPC 8 full level

**A61K 9/12** (2006.01)

## CPC (source: EP)

**A61K 9/008** (2013.01); **A61K 9/124** (2013.01); **A61M 11/041** (2013.01); **A61M 11/044** (2014.02); **A61M 2016/0021** (2013.01); **A61M 2016/0027** (2013.01); **A61M 2202/0476** (2013.01); **A61M 2205/3653** (2013.01); **A61M 2205/502** (2013.01); **A61M 2205/8206** (2013.01)

## Citation (search report)

- [X] GB 2326334 A 19981223 - CHIESI FARMA SPA [IT]
- [X] WO 0249616 A1 20020627 - ASTRAZENECA AB [SE], et al
- [X] WO 9619197 A1 19960627 - ASTRA AB [SE], et al
- [X] WO 9629985 A1 19961003 - MINNESOTA MINING & MFG [US]
- [X] FR 2806077 A1 20010914 - SOLVAY [BE]
- [X] US 6242472 B1 20010605 - SEKINS K MICHAEL [US], et al
- [X] WO 0030608 A1 20000602 - CHIESI FARMA SPA [IT], et al
- [X] WO 9619198 A1 19960627 - ASTRA AB [SE], et al
- [X] WO 0195881 A1 20011220 - GLAXO GROUP LTD [GB], et al
- [X] US 5562608 A 19961008 - SEKINS K MICHAEL [US], et al
- [X] WO 9219300 A1 19921112 - UNIV PITTSBURGH [US]
- See references of WO 2004071488A1

## Citation (examination)

M. E. AULTON: "Pharmaceutics: The Science of Dosage Form Design.", 2002, CHURCHILL LIVINGSTONE, article KEVIN TAYLOR: "Pulmonary drug delivery", pages: 473 - 487

## Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

## DOCDB simple family (publication)

**WO 2004071488 A1 20040826**; AU 2003293528 A1 20040906; EP 1599184 A1 20051130; EP 1599184 A4 20090624; JP 2006516545 A 20060706

## DOCDB simple family (application)

**US 0339561 W 20031215**; AU 2003293528 A 20031215; EP 03790479 A 20031215; JP 2004568322 A 20031215